ESMO 2020 Highlights With Cora Sternberg, MD, FACP
TROPHY U-01 cohort 1 is a phase 2 open-label study of sacituzumab govitecan in patients with metastatic urothelial cancer and disease progression after both platinum-based regimens and checkpoint inhibitors.
ESMO 2020 Highlights With Aditya Bardia, MD, MPH
Aditya Bardia, MD, MPH, discusses the results of the ASCENT trial in triple-negative breast cancer.
Role of Trop-2 as an Actionable Biomarker in Solid Tumors
Trophoblast cell surface antigen 2 is a glycoprotein that spans the epithelial membrane surface and plays a role in cell self-renewal, proliferation, and transformation.
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
2 Commerce Drive Cranbury, NJ 08512